Secondary amyloidosis differential diagnosis: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 390: Line 390:
|-
|-
| rowspan="6"  style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''Polyneuropathy'''
| rowspan="6"  style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''Polyneuropathy'''
|'''[[POEMS syndrome]] (Demyelinating)'''
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[POEMS syndrome]] (Demyelinating)'''
|
|
* [[Monoclonal]] [[plasma cell]] proliferation
* [[Monoclonal]] [[plasma cell]] proliferation
Line 411: Line 411:
|
|
|-
|-
|'''[[Metabolic syndrome|Metabolic Syndrome]] (Axonal pathology)'''
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Metabolic syndrome|Metabolic Syndrome]] (Axonal pathology)'''
|
|
* [[Diabetes mellitus]]
* [[Diabetes mellitus]]
Line 438: Line 438:
* [[Foot care]]
* [[Foot care]]
|-
|-
|'''[[Vitamin deficiencies|Vitamin Deficiencies]] (Axonal Pathology)'''
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Vitamin deficiencies|Vitamin Deficiencies]] (Axonal Pathology)'''
|
|
* [[Vitamin B12 deficiency]] (Decreased [[S-Adenosyl methionine|S-adenosyl methionine]])
* [[Vitamin B12 deficiency]] (Decreased [[S-Adenosyl methionine|S-adenosyl methionine]])
Line 464: Line 464:
* [[Vitamin B12]] supplement ([[parenteral]])
* [[Vitamin B12]] supplement ([[parenteral]])
|-
|-
|'''[[Guillain-Barré syndrome|Guillain-Barre Syndrome]] (Demyelinating)'''
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Guillain-Barré syndrome|Guillain-Barre Syndrome]] (Demyelinating)'''
|
|
* [[Anti-ganglioside antibodies|Anti-ganglioside]] and anti-[[myelin]] antibodies
* [[Anti-ganglioside antibodies|Anti-ganglioside]] and anti-[[myelin]] antibodies
Line 498: Line 498:
* [[DVT]]/[[PE]] [[prevention]]
* [[DVT]]/[[PE]] [[prevention]]
|-
|-
|'''[[Chronic inflammatory demyelinating polyneuropathy|Chronic Inflammatory Demyelinating Polyneuropathy]] (CIDP) (Mixed axonal and demyelinatiing)'''
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Chronic inflammatory demyelinating polyneuropathy|Chronic Inflammatory Demyelinating Polyneuropathy]] (CIDP) (Mixed axonal and demyelinatiing)'''
|
|
* Abnormal [[immune response]] (both [[Immunoglobulin G|IgG]] based [[Humoral immunity|humoral]] and [[Cell mediated immunity|T-Cell mediated]]) response to unknown [[antigen]] (possible culprits include [[myelin]] [[proteins]] P0, P2 and PMP22)
* Abnormal [[immune response]] (both [[Immunoglobulin G|IgG]] based [[Humoral immunity|humoral]] and [[Cell mediated immunity|T-Cell mediated]]) response to unknown [[antigen]] (possible culprits include [[myelin]] [[proteins]] P0, P2 and PMP22)
Line 524: Line 524:
* [[Immunosupressive drug|Immunosupressants]] ([[Alemtuzumab|Alemtuzemab]] [[Azathioprine]] [[Cyclophosphamide]] [[Cyclosporine|Cyclosporin]] [[Etanercept]] [[Interferon-alpha]])
* [[Immunosupressive drug|Immunosupressants]] ([[Alemtuzumab|Alemtuzemab]] [[Azathioprine]] [[Cyclophosphamide]] [[Cyclosporine|Cyclosporin]] [[Etanercept]] [[Interferon-alpha]])
|-
|-
|'''[[Multifocal motor neuropathy|Multifocal Motor Neuropathy]]'''
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Multifocal motor neuropathy|Multifocal Motor Neuropathy]]'''
|
|
* [[Immune response|Abnormal immune response]] ([[Anti-ganglioside antibodies|Anti ganglioside]] [[Anti-ganglioside antibodies|GM-1]] [[IgM]] [[antibodies]])
* [[Immune response|Abnormal immune response]] ([[Anti-ganglioside antibodies|Anti ganglioside]] [[Anti-ganglioside antibodies|GM-1]] [[IgM]] [[antibodies]])
Line 552: Line 552:
| style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|'''Therapy'''}}
| style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|'''Therapy'''}}
|-
|-
| rowspan="7" |'''Organomegaly (Hepatosplenomegaly and Lymphadenopathy)'''
| rowspan="7"  style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''Organomegaly (Hepatosplenomegaly and Lymphadenopathy)'''
|'''[[Malaria]]'''
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Malaria]]'''
|
|
* [[Plasmodium falciparum]]
* [[Plasmodium falciparum]]
Line 591: Line 591:
** [[Atovaquone-Proguanil|Atovaquone plus proguanil]]
** [[Atovaquone-Proguanil|Atovaquone plus proguanil]]
|-
|-
|'''[[Kala-azar]]'''
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Kala-azar]]'''
|
|
* [[Leishmaniasis|Leshmania donovani]]
* [[Leishmaniasis|Leshmania donovani]]
Line 616: Line 616:
* [[Pentamidine]]
* [[Pentamidine]]
|-
|-
|'''[[Hepatitis|Infective Hepatitis]]'''
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Hepatitis|Infective Hepatitis]]'''
|
|
* [[Hepatitis A virus|Hepatitis A virus (HAV)]]
* [[Hepatitis A virus|Hepatitis A virus (HAV)]]
Line 653: Line 653:
* [[Antivirals|Nucleotide analogs]]
* [[Antivirals|Nucleotide analogs]]
|-
|-
|'''[[Chronic myelogenous leukemia|Chronic Myelogenous Leukemia]] (CML)'''
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Chronic myelogenous leukemia|Chronic Myelogenous Leukemia]] (CML)'''
|
|
* [[Philadelphia chromosome|BCR/ABL gene]] fusion product due to [[Chromosomal translocation|translocation]] [[mutation]] [[Philadelphia chromosome|t(9;22)]](q34;q11)
* [[Philadelphia chromosome|BCR/ABL gene]] fusion product due to [[Chromosomal translocation|translocation]] [[mutation]] [[Philadelphia chromosome|t(9;22)]](q34;q11)
Line 697: Line 697:
* [[Stem cell transplantation]]
* [[Stem cell transplantation]]
|-
|-
|'''[[Lymphoma]]'''
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Lymphoma]]'''
|
|
* Various causes based on type:
* Various causes based on type:
Line 718: Line 718:
|
|
|-
|-
|'''[[Primary amyloidosis|Primary (AL) Amyloidosis]]'''
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Primary amyloidosis|Primary (AL) Amyloidosis]]'''
|
|
* Aggregation and deposition of [[immunoglobulin light chains]] that are usually produced by [[plasma cell]] clones
* Aggregation and deposition of [[immunoglobulin light chains]] that are usually produced by [[plasma cell]] clones
Line 738: Line 738:
* Stem cell transplantation
* Stem cell transplantation
|-
|-
|'''[[Gaucher's disease|Gaucher's Disease]]'''
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Gaucher's disease|Gaucher's Disease]]'''
|
|
* [[GBA (gene)|GBA gene]] [[mutation]]
* [[GBA (gene)|GBA gene]] [[mutation]]

Revision as of 19:13, 5 November 2019

link=https://www.wikidoc.org/index.php/Secondary amyloidosis#Overview
link=https://www.wikidoc.org/index.php/Secondary amyloidosis#Overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sahar Memar Montazerin, M.D.[2]

Overview

Secondary amyloidosis needs to be differentiated from other conditions causing nephrotic syndrome, hepatosplenomegaly, and peripheral neuropathy.

Differentiating Amyloidosis from other Diseases

Secondary amyloidosis needs to be differentiated from other conditions causing nephrotic syndrome, hepatosplenomegaly, and peripheral neuropathy.

Differential diagnosis of secondary amyloidosis
Nephrotic syndrome causes[1][2][3][4][5][6][7]
Hepatosplenomegaly causes[8][9]
  • Metabolic disorders
  • Chronic liver disease and portal hypertension
  • Infectoins
  • Hematologic disorders
  • Rare disorders
Peripheral neuropathy causes[10][11][12][13][14][15][16][17][18][19][20]
  • Neurologic disorders
  • Inflammatory disorders
  • Toxins
  • Vitamin deficiencies
  • Metabolic disorders
  • Genetic disorders
Organ System Involvement Differential Diagnosis Causes Clinical Features Laboratory Findings Gold Standard Test Therapy
Nephrotic Syndrome and Renal Failure Secondary (AA) Amyloidosis
  • Biopsy and congo-red staining of the sample
Primary (AL) Amyloidosis


Diabetic Nephropathy
Minimal Change Disease
Focal Segmental Glomerulosclerosis
  • Biopsy:
    • Podocyte foot process effacement
    • Capillary lumen abolished by the segmental increase in matrix
Fabry's Disease
  • Deficient alpha galactosidase A
Light Chain Deposition Disease
  • Biopsy:
    • Non-amyloid granules
Membranous Glomerulonephritis
Fibrillary-Immunotactoid Glomerulopathy
  • Biopsy:
    • Polycloncal IgG deposits
    • Infiltration of glomerular structures by amorphous acellular material (nonbranching fibrils 12-24nm in diameter)
    • Ig heavy-chain and one light-chain subclass
Organ System Involvement Differential Diagnosis Causes Clinical Features Laboratory Findings Gold Standard Test Therapy
Polyneuropathy POEMS syndrome (Demyelinating)
Metabolic Syndrome (Axonal pathology)
Vitamin Deficiencies (Axonal Pathology)



Guillain-Barre Syndrome (Demyelinating)
  • Delayed F waves
  • Clinical diagnostic criteria (progressive weakness of more than two limbs, areflexia, and progression for no more than four weeks)
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Mixed axonal and demyelinatiing)


  • EFNS/PNS criteria
  • Koski criteria
Multifocal Motor Neuropathy
  • Progressive, asymmetric, distal and upper limb predominant weakness
  • No significant sensory abnormalities
  • Areflexia
  • Clinical criteria (EFNS/PNS):
    • Slowly progressive or step-wise progressive, focal, asymmetric limb weakness; i.e., motor involvement in the motor nerve distribution of at least two nerves for > 1 month.
    • No objective sensory abnormalities except for minor vibration sense abnormalities in the lower limbs


Organ System Involvement Differential Diagnosis Causes Features Laboratory Findings Gold Standard Test Therapy
Organomegaly (Hepatosplenomegaly and Lymphadenopathy) Malaria
Kala-azar


Infective Hepatitis
Chronic Myelogenous Leukemia (CML)
Lymphoma
Primary (AL) Amyloidosis
  • Typical green birefringence under polarized light after Congo red staining (appears in red under normal light)
  • Congo red staining
  • Melphalan-prednisone/dexamethasone
  • Dexamethasone plus Cyclophosphamide-thalidomide
  • Stem cell transplantation
Gaucher's Disease

References

  1. Rivera F, López-Gómez JM, Pérez-García R (September 2004). "Clinicopathologic correlations of renal pathology in Spain". Kidney Int. 66 (3): 898–904. doi:10.1111/j.1523-1755.2004.00833.x. PMID 15327378.
  2. Haas M, Meehan SM, Karrison TG, Spargo BH (November 1997). "Changing etiologies of unexplained adult nephrotic syndrome: a comparison of renal biopsy findings from 1976-1979 and 1995-1997". Am. J. Kidney Dis. 30 (5): 621–31. PMID 9370176.
  3. Simon P, Ramee MP, Boulahrouz R, Stanescu C, Charasse C, Ang KS, Leonetti F, Cam G, Laruelle E, Autuly V, Rioux N (September 2004). "Epidemiologic data of primary glomerular diseases in western France". Kidney Int. 66 (3): 905–8. doi:10.1111/j.1523-1755.2004.00834.x. PMID 15327379.
  4. Braden GL, Mulhern JG, O'Shea MH, Nash SV, Ucci AA, Germain MJ (May 2000). "Changing incidence of glomerular diseases in adults". Am. J. Kidney Dis. 35 (5): 878–83. PMID 10793022.
  5. Malafronte P, Mastroianni-Kirsztajn G, Betônico GN, Romão JE, Alves MA, Carvalho MF, Viera Neto OM, Cadaval RA, Bérgamo RR, Woronik V, Sens YA, Marrocos MS, Barros RT (November 2006). "Paulista Registry of glomerulonephritis: 5-year data report". Nephrol. Dial. Transplant. 21 (11): 3098–105. doi:10.1093/ndt/gfl237. PMID 16968733.
  6. Bahiense-Oliveira M, Saldanha LB, Mota EL, Penna DO, Barros RT, Romão-Junior JE (February 2004). "Primary glomerular diseases in Brazil (1979-1999): is the frequency of focal and segmental glomerulosclerosis increasing?". Clin. Nephrol. 61 (2): 90–7. PMID 14989627.
  7. Gesualdo L, Di Palma AM, Morrone LF, Strippoli GF, Schena FP (September 2004). "The Italian experience of the national registry of renal biopsies". Kidney Int. 66 (3): 890–4. doi:10.1111/j.1523-1755.2004.00831.x. PMID 15327376.
  8. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:77 ISBN 1591032016
  9. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:68 ISBN 140510368X
  10. Marchettini P, Lacerenza M, Mauri E, Marangoni C (2006). "Painful peripheral neuropathies". Curr Neuropharmacol. 4 (3): 175–81. PMC 2430688. PMID 18615140.
  11. Watson JC, Dyck PJ (2015). "Peripheral Neuropathy: A Practical Approach to Diagnosis and Symptom Management". Mayo Clin Proc. 90 (7): 940–51. doi:10.1016/j.mayocp.2015.05.004. PMID 26141332.
  12. Hughes RA (2002). "Peripheral neuropathy". BMJ. 324 (7335): 466–9. PMC 1122393. PMID 11859051.
  13. Colloca L, Ludman T, Bouhassira D, Baron R, Dickenson AH, Yarnitsky D; et al. (2017). "Neuropathic pain". Nat Rev Dis Primers. 3: 17002. doi:10.1038/nrdp.2017.2. PMC 5371025. PMID 28205574.
  14. Juster-Switlyk K, Smith AG (2016). "Updates in diabetic peripheral neuropathy". F1000Res. 5. doi:10.12688/f1000research.7898.1. PMC 4847561. PMID 27158461.
  15. Bansal V, Kalita J, Misra UK (2006). "Diabetic neuropathy". Postgrad Med J. 82 (964): 95–100. doi:10.1136/pgmj.2005.036137. PMC 2596705. PMID 16461471.
  16. Hanewinckel R, Ikram MA, Van Doorn PA (2016). "Peripheral neuropathies". Handb Clin Neurol. 138: 263–82. doi:10.1016/B978-0-12-802973-2.00015-X. PMID 27637963.
  17. Argov Z, Mastaglia FL (1979). "Drug-induced peripheral neuropathies". Br Med J. 1 (6164): 663–6. PMC 1598252. PMID 219931.
  18. Remiche G, Kadhim H, Maris C, Mavroudakis N (2013). "[Peripheral neuropathies, from diagnosis to treatment, review of the literature and lessons from the local experience]". Rev Med Brux. 34 (4): 211–20. PMID 24195230.
  19. Phan T, McLeod JG, Pollard JD, Peiris O, Rohan A, Halpern JP (1995). "Peripheral neuropathy associated with simvastatin". J Neurol Neurosurg Psychiatry. 58 (5): 625–8. PMC 1073498. PMID 7745415.
  20. Cohen JA, Gross KF (1990). "Peripheral neuropathy: causes and management in the elderly". Geriatrics. 45 (2): 21–6, 31–4. PMID 2153610.